top of page

SEYLTX

News and Events

Press Releases

June 6, 2025

Seyltx Expands GluN2B Antagonist Pipeline with Clinical-Stage and Small-Molecule Candidates for Chronic Cough

Company enters into option agreement with NeurOp to in-license novel GluN2B antagonists Compounds include a highly potent and selective...

June 5, 2025

Seyltx Announces Positive Non-Human Primate (NHP) and Additional In Vivo Data for its Centrally Acting Inhibitor of GluN2B in Chronic Cough, Paving the Way for Optimized Later-Stage Phase 2 Trials

Results will be presented at the American Cough Conference on June 7, 2025 NHP receptor occupancy studies indicate increasing the dose in...

July 16, 2024

Seyltx Announces Positive Pre-Clinical Dose-Ranging Data with Its Selective Oral Inhibitor of GluN2B Illustrating Near-Complete Suppression of Refractory Chronic Cough within the Therapeutic Index

CAMBRIDGE, MA, JULY 16, 2024 (GLOBE NEWSWIRE) – Seyltx, Inc. (“Seyltx” or the “Company”), a clinical-stage biopharmaceutical company...

July 11, 2024

Seyltx Announces Results of Electronic Health Record Analysis to Determine the Prevalence of Refractory Chronic Cough

CAMBRIDGE, MA - JULY 09, 2024 -Data will be presented at the London International Cough Symposium on July 18, 2024 - 54,958,289 adult...

Scientific Publications

Dose-Ranging of The Selective GluN2B Allosteric Inhibitor Ifenprodil Illustrates Near-Complete Cough Suppression Within The Therapeutic Index

Presented at the London International Cough Symposium, July 18-29, London, UK

A Composite Diagnostic Signature for Accurate Identification of Refractory Chronic Cough (RCC) Patients from Electronic Health Records (EHR)

Presented at the London International Cough Symposium, July 18-29, London, UK

bottom of page